Alpha lipoic acid for dementia.
Alpha lipoic acid for dementia.
复制标题
α-硫辛酸用于治疗痴呆症。
DOI：
--
复制
发表时间：
2004
影响因子：
8.4
通讯作者：
R. Howard
中科院分区：
文献类型：
--
作者：
A. Klugman;Justin Sauer;Naji Tabet;R. Howard
背景
氧化过程与包括阿尔茨海默病在内的神经退行性痴呆的发病机制有关。保护中枢神经系统免受这些损伤机制可能是一种有用的治疗方法。α-硫辛酸(ALA)是一种内源性抗氧化剂，它以氧化和还原的形式中断细胞的氧化过程。这些特性可能使ALA有资格在痴呆症患者的治疗中发挥调节作用。
目标
目的：评价α-硫辛酸在痴呆治疗中的作用和临床疗效。
搜索策略
检索Cochrane痴呆症和认知改善小组(CDCIG)2003年2月3日的专门登记册，检索词‘α-硫辛酸’和‘硫辛酸’。CDCIG专门登记册定期更新，包含来自所有主要卫生保健数据库(MEDLINE、EMBASE、PERICINFO、CINAHL)以及许多试验数据库的记录。
遴选标准
所有检测α-硫辛酸治疗痴呆症疗效的双盲随机安慰剂对照试验
数据收集和分析
没有找到符合选择标准的试验
主要成果
不能进行荟萃分析。系统地搜索Cochrane痴呆症和认知改善小组的专门登记册，以及正在进行的和未发表的试验登记册，都没有发现任何调查ALA治疗痴呆症的研究。
评审者的结论
在缺乏研究丙氨酸治疗痴呆症的随机双盲安慰剂对照试验的情况下，没有证据来探索任何潜在的影响。在试验数据可供分析之前，ALA不能推荐用于痴呆症患者。
BACKGROUND
Oxidative processes have been implicated in the pathogenesis of neurodegenerative dementias including Alzheimer's disease. Protecting the central nervous system against these damaging mechanisms may be a useful therapeutic approach. Alpha lipoic acid (ALA) is an endogenous antioxidant that interrupts cellular oxidative processes in both its oxidized and reduced forms. These properties might qualify ALA for a modulatory role in the treatment of people with dementia.
OBJECTIVES
To assess the role and clinical efficacy of alpha lipoic acid in the treatment of dementia.
SEARCH STRATEGY
A search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG) on 3 February 2003 using the terms 'alpha lipoic acid' and 'thioctic'. The CDCIG Specialized register is updated regularly and contains records from all major health care databases (MEDLINE, EMBASE, PsycInfo, CINAHL) as well as from many trials databases.
SELECTION CRITERIA
All double-blind randomized placebo-controlled trials examining the efficacy of alpha lipoic acid in dementia
DATA COLLECTION AND ANALYSIS
No trials were found that met the selection criteria
MAIN RESULTS
No meta-analysis could be performed. A systematic search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group, as well as registers of ongoing and unpublished trials could not identify any studies investigating the use of ALA for dementia.
REVIEWER'S CONCLUSIONS
In the absence of randomized double-blind placebo-controlled trials investigating ALA for dementia, no evidence exists to explore any potential effects. Until data from trials become available for analysis, ALA cannot be recommended for people with dementia.
DOI：
10.1016/0006-291x(90)91971-t
发表时间：
1990-06-29
影响因子：
3.1
作者：
KAGAN, V;SERBINOVA, E;PACKER, L
通讯作者：
PACKER, L
影响因子：
2.9
作者：
Huang, XD;Atwood, CS;Bush, AI
通讯作者：
Bush, AI